Authors:
Perno, CF
Cozzi-Lepri, A
Balotta, C
Forbici, F
Violin, M
Bertoli, A
Facchi, G
Pezzotti, P
Cadeo, G
Tositti, G
Pasquinucci, S
Pauluzzi, S
Scalzini, A
Salassa, B
Vincenti, A
Phillips, AN
Dianzani, F
Appice, A
Angarano, G
Monno, L
Ippolito, G
Moroni, M
Monforte, AD
Citation: Cf. Perno et al., Secondary mutations in the protease region of human immunodeficiency virusand virologic failure in drug-naive patients treated with protease inhibitor-based therapy, J INFEC DIS, 184(8), 2001, pp. 983-991
Authors:
Floridia, M
Bucciardini, R
Ricciardulli, D
Fragola, V
Pirillo, MF
Weimer, LE
Tomino, C
Giannini, G
Galluzzo, CM
Andreotti, M
Cargnel, A
Alberici, F
De Rienzo, B
Leoncini, F
Fiaccadori, F
Francisci, D
Grillone, W
Ortona, T
Piazza, S
Scalzini, A
Nigra, E
Tumietto, F
Vella, S
Citation: M. Floridia et al., A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease, J ACQ IMM D, 20(1), 1999, pp. 11-19
Authors:
Matteelli, A
Olliaro, P
Signorini, L
Cadeo, G
Scalzini, A
Bonazzi, L
Caligaris, S
Tomasoni, L
Tebaldi, A
Carosi, G
Citation: A. Matteelli et al., Tolerability of twice-weekly rifabutin-isoniazid combinations versus dailyisoniazid for latent tuberculosis in HIV-infected subjects: a pilot study, INT J TUBE, 3(11), 1999, pp. 1043-1046